E M Parker

Summary

Affiliation: Schering-Plough Research Institute
Country: USA

Publications

  1. ncbi GR231118 (1229U91) and other analogues of the C-terminus of neuropeptide Y are potent neuropeptide Y Y1 receptor antagonists and neuropeptide Y Y4 receptor agonists
    E M Parker
    Department of Central Nervous System and Cardiovascular Research, Schering Plough Research Institute, Kenilworth, NJ 07033 0539, USA
    Eur J Pharmacol 349:97-105. 1998
  2. ncbi Neuropeptide Y receptors as targets for anti-obesity drug development: perspective and current status
    Eric Parker
    Department of CNS and Cardiovascular Research, Schering Plough Research Institute, Mail Stop K 15 2 2760, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA
    Eur J Pharmacol 440:173-87. 2002
  3. ncbi [D-Trp(34)] neuropeptide Y is a potent and selective neuropeptide Y Y(5) receptor agonist with dramatic effects on food intake
    E M Parker
    Department of CNS and Cardiovascular Research, Schering Plough Research Institute, Kenilworth, NJ 07033, USA
    Peptides 21:393-9. 2000
  4. ncbi Rapamycin, but not FK506 and GPI-1046, increases neurite outgrowth in PC12 cells by inhibiting cell cycle progression
    E M Parker
    Department of CNS and Cardiovascular Research, Mail Stop K 15 3 3600, Schering Plough Research Institute, 2015 Galloping Hill Road, NJ 07033, Kenilworth, USA
    Neuropharmacology 39:1913-9. 2000
  5. ncbi Activation of the NPY Y5 receptor regulates both feeding and energy expenditure
    J J Hwa
    Department of CNS, Schering Plough Research Institute, Kenilworth, New Jersey 07033, USA
    Am J Physiol 277:R1428-34. 1999
  6. ncbi Potent pyrrolidine- and piperidine-based BACE-1 inhibitors
    U Iserloh
    Department of Chemical Research, Schering Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA
    Bioorg Med Chem Lett 18:414-7. 2008
  7. ncbi Pharmacological characterization of the cloned neuropeptide Y y(6) receptor
    D E Mullins
    Department of Central Nervous System and Cardiovascular Research, Schering Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA
    Eur J Pharmacol 395:87-93. 2000
  8. ncbi Rational design of novel, potent piperazinone and imidazolidinone BACE1 inhibitors
    J N Cumming
    Schering Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA
    Bioorg Med Chem Lett 18:3236-41. 2008
  9. ncbi Central melanocortin system modulates energy intake and expenditure of obese and lean Zucker rats
    J J Hwa
    Schering Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, USA
    Am J Physiol Regul Integr Comp Physiol 281:R444-51. 2001
  10. ncbi Molecular approaches to the discovery of new treatments for obesity
    C D Strader
    Department of CNS and Cardiovascular Research, Schering Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA
    Curr Opin Chem Biol 1:204-9. 1997

Collaborators

Detail Information

Publications16

  1. ncbi GR231118 (1229U91) and other analogues of the C-terminus of neuropeptide Y are potent neuropeptide Y Y1 receptor antagonists and neuropeptide Y Y4 receptor agonists
    E M Parker
    Department of Central Nervous System and Cardiovascular Research, Schering Plough Research Institute, Kenilworth, NJ 07033 0539, USA
    Eur J Pharmacol 349:97-105. 1998
    ....
  2. ncbi Neuropeptide Y receptors as targets for anti-obesity drug development: perspective and current status
    Eric Parker
    Department of CNS and Cardiovascular Research, Schering Plough Research Institute, Mail Stop K 15 2 2760, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA
    Eur J Pharmacol 440:173-87. 2002
    ....
  3. ncbi [D-Trp(34)] neuropeptide Y is a potent and selective neuropeptide Y Y(5) receptor agonist with dramatic effects on food intake
    E M Parker
    Department of CNS and Cardiovascular Research, Schering Plough Research Institute, Kenilworth, NJ 07033, USA
    Peptides 21:393-9. 2000
    ..These data demonstrate that [D-Trp(34)]NPY is a useful tool for studies aimed at determining the physiological roles of the NPY Y(5) receptor...
  4. ncbi Rapamycin, but not FK506 and GPI-1046, increases neurite outgrowth in PC12 cells by inhibiting cell cycle progression
    E M Parker
    Department of CNS and Cardiovascular Research, Mail Stop K 15 3 3600, Schering Plough Research Institute, 2015 Galloping Hill Road, NJ 07033, Kenilworth, USA
    Neuropharmacology 39:1913-9. 2000
    ..The neuroprotective effect of FK506 and rapamycin against cerebral ischemia is probably not due to differentiation of neuronal precursors or stimulation of neuronal regeneration...
  5. ncbi Activation of the NPY Y5 receptor regulates both feeding and energy expenditure
    J J Hwa
    Department of CNS, Schering Plough Research Institute, Kenilworth, New Jersey 07033, USA
    Am J Physiol 277:R1428-34. 1999
    ..These data suggest that the NPY Y5-receptor subtype not only mediates the feeding response of NPY but also contributes to brown fat temperature and energy expenditure regulation...
  6. ncbi Potent pyrrolidine- and piperidine-based BACE-1 inhibitors
    U Iserloh
    Department of Chemical Research, Schering Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA
    Bioorg Med Chem Lett 18:414-7. 2008
    ..Extensive SAR studies on both pyrrolidines and piperidines ultimately led to inhibitor 2f, one of the most potent inhibitors synthesized to date...
  7. ncbi Pharmacological characterization of the cloned neuropeptide Y y(6) receptor
    D E Mullins
    Department of Central Nervous System and Cardiovascular Research, Schering Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA
    Eur J Pharmacol 395:87-93. 2000
    ..Although the function of the neuropeptide Y y(6) receptor remains to be elucidated, its pharmacology is not consistent with a role in appetite regulation...
  8. ncbi Rational design of novel, potent piperazinone and imidazolidinone BACE1 inhibitors
    J N Cumming
    Schering Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA
    Bioorg Med Chem Lett 18:3236-41. 2008
    ..The key feature of both series is a cyclic amine motif specifically crafted to achieve interactions with both the flap and with the S2' pocket...
  9. ncbi Central melanocortin system modulates energy intake and expenditure of obese and lean Zucker rats
    J J Hwa
    Schering Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, USA
    Am J Physiol Regul Integr Comp Physiol 281:R444-51. 2001
    ..Our data suggest that a melanocortin receptor agonist can induce weight loss by increasing energy expenditure and promoting body fat utilization in addition to its inhibitory effects on food intake in both obese and lean Zucker rats...
  10. ncbi Molecular approaches to the discovery of new treatments for obesity
    C D Strader
    Department of CNS and Cardiovascular Research, Schering Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA
    Curr Opin Chem Biol 1:204-9. 1997
    ..Specific subtypes of the receptors for these neurotransmitters represent promising molecular targets for the discovery of new drugs for the treatment of obesity...
  11. ncbi Calpain inhibitor I increases beta-amyloid peptide production by inhibiting the degradation of the substrate of gamma-secretase. Evidence that substrate availability limits beta-amyloid peptide production
    L Zhang
    Department of Central Nervous System and Cardiovascular Research, Schering Plough Research Institute, Kenilworth, New Jersey 07033, USA
    J Biol Chem 274:8966-72. 1999
    ..Rather, Abeta42 secretion may be more dependent on C100 substrate concentration than Abeta40 secretion...
  12. ncbi Comparison of the V1b antagonist, SSR149415, and the CRF1 antagonist, CP-154,526, in rodent models of anxiety and depression
    R A Hodgson
    Department of Neurobiology, Schering Plough Research Institute, Kenilworth, NJ 07033, USA
    Pharmacol Biochem Behav 86:431-40. 2007
    ..This work demonstrates the different profiles of V1b and CRF1 receptor antagonists and supports both approaches in the treatment of affective disorders...
  13. ncbi Characterization of the nociceptin receptor (ORL-1) agonist, Ro64-6198, in tests of anxiety across multiple species
    G B Varty
    Department of Neurobiology, K 15 2600, Schering Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA
    Psychopharmacology (Berl) 182:132-43. 2005
    ..Previous studies have demonstrated behaviors indicative of anxiolysis in rats pretreated with the nociceptin receptor (opioid receptor like-1, ORL-1) agonist, Ro64-6198...
  14. ncbi Discovery of an orally efficaceous 4-phenoxypyrrolidine-based BACE-1 inhibitor
    U Iserloh
    Department of Chemical Research, Schering Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA
    Bioorg Med Chem Lett 18:418-22. 2008
    ..Due to its favorable overall profile, 11 has been extensively profiled in various in vivo settings...
  15. ncbi Genomic organization and functional characterization of the mouse GalR1 galanin receptor
    S Wang
    Department of CNS CV Biological Research, Schering Plough Research Institute, Kenilworth, NJ 07033, USA
    FEBS Lett 411:225-30. 1997
    ..Functional analysis of the encoded cDNA revealed active ligand binding and intracellular signaling. The expression is detected in brain, spinal cord, heart and skeletal muscle...
  16. ncbi Measuring human beta-secretase (BACE1) activity using homogeneous time-resolved fluorescence
    Matthew E Kennedy
    CNS Cardiovascular Research, Schering Plough Research Institute, Kenilworth, NJ 07033, USA
    Anal Biochem 319:49-55. 2003
    ....